Dear Sir or Madam:

The SEER website has improved, but the utility of the statistics for non-Hodgkin's lymphomas continue to suffer because subtypes of the disease are not yet provided. For comparison purposes SEER provides the following useful categories for Leukemias:

Lymphocytic Leukemia

- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Myeloid and Monocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia

Non-Hodgkin's Lymphoma:

- none

As you know, incidence, prevalence and survival vary significantly based on subtypes of lymphoma. Trends in survival also vary significantly based on the clinical tempo of the disease - aggressive versus indolent, as does, presumably, conditional survival.

We do not know yet what NHL entities are available to SEER (in the raw data sets), but we ask that you provide subtype specific information on NHL, perhaps as outlined on the next page, and a timetable for achieving this important goal.
Proposed categories for lymphomas, perhaps as a subset of blood cancers:

**Lymphomas**
- Non-Hodgkin's lymphoma
  - Aggressive
    - DLBCL
    - T-cell
    - MCL
    - Other (Aggressive - defined entities)
  - Indolent
    - Follicular
    - MALT
    - T-cell
    - Other (Indolent - defined entities)
- Hodgkin's Lymphoma
  - Subtypes?

*Note: As you know, CLL is b-lymphocyte cancer. Presumably, it's classified as a leukemia based on where it presents and other factors, but many experts considered it a lymphoma, based on the cell of origin: b-lymphocyte.*

Thank you for your attention to our proposal and comments. We look forward to your reply.

Sincerely,

Karl Schwartz

President and co-founder, Patients Against Lymphoma
Patient Consultant to the FDA/Oncologic Drug Advisory Committee (ODAC)
Participant: NCI Progress Review Group for Blood Cancers (LMPRG)
Participant: Biospecimen Access and Ethical, Legal, and Policy Issues Workshop (ELP)
Participant: Custodianship and Ownership Issues in Biospecimen Research Symposium